Abstract. Recent studies have shown that circular RNAs (circRNAs) exhibit differential expression in certain diseases. However, to the best of our knowledge, maternal fetal-derived circRNAs and mRNAs associated with Down's syndrome (DS) have not yet been investigated. A total of 12 umbilical cord blood samples were collected from pregnant women, including six women carrying fetuses with DS (diagnosed by G-banding karyotype analysis), and six women carrying fetuses without DS. In addition, 12 peripheral blood samples were obtained from children, including six children with DS and six children without DS. Gene chip technology was used to screen for differentially expressed circRNAs and mRNAs in the cord blood samples, and were subsequently verified by reverse transcription-quantitative polymerase chain reaction in peripheral blood from the children to identify potential biomarkers. Furthermore, circRNA/microRNA (miRNA) interactions were predicted using Arraystar miRNA target prediction software. There was a significant difference in the expression of hsa_circRNA_103127, hsa_circRNA_103112 and hsa_circRNA_104907 between cord blood obtained from the women carrying fetuses with and without DS, and between peripheral blood obtained from children with and without DS (P<0.01). As hsa_circRNA_103112 exhibited significant differences in expression between cord blood obtained from the women carrying fetuses with and without DS and between peripheral blood obtained from children with and without DS, its corresponding gene, ubiquitin specific peptidase 25, may be involved in the pathogenesis of the condition. These results suggested that hsa_circRNA_103112 may be upregulated in individuals with DS, resulting in an expression imbalance of diploid genes through interactions among circRNA, miRNA and mRNA. Therefore, the level of hsa_circRNA_103112 in the peripheral blood of a pregnant woman may serve as potential biomarker of fetal DS during non-invasive prenatal screening.

Introduction

Down's syndrome (DS), or trisomy 21, is caused by the presence of three copies of chromosome 21 and is the most common genetic cause of intellectual disability (1) DS has an incidence of up to 1 in 700 live births (2), and this incidence increases with increasing maternal age (3). DS is characterized by mild-to-moderate learning disabilities, craniofacial abnormalities and hypotonia (4), and is typically accompanied by more than 80 diseases such as congenital heart disease, low immunity, leukaemia (5). DS is associated with financial burden on the family and society, and there is no effective therapy for the chromosomal abnormalities. Traditional prenatal screening and diagnostic methods are associated with several shortcomings, and the clinical application of novel non-invasive prenatal diagnostic methods are restricted by various factors (6). Therefore, there is a requirement for the development of an efficient, accurate and cost-effective screening method.

Circular RNAs (circRNAs) are a type of RNA, which unlike linear RNA, have joined 5’ and 3’ ends that form a continuous loop (7), a structure that provides resistance against exonucleases and further differentiates them from other types of RNA (8). circRNAs are a class of endogenous noncoding RNAs produced by the non-canonical form of alternative splicing (7,9). Developments in bioinformatics analysis and
RNA deep sequencing technology revealed that circRNAs are abundant, conserved and stable in mammalian cells (10-16). Previous studies demonstrated that certain circRNAs not only act as competing endogenous RNA for gene expression regulation, but also repress the function of microRNAs (miRNAs/miRs) by binding to miRNA response elements (MREs), thereby regulating the expression level of other related RNAs (13,17,18). Studies have also shown that imbalances in the expression of certain miRNAs may lead to extensive changes in mRNA and protein expression, and play an important role in the development and progression of disease (19,20). In addition, certain circRNAs serve as a template during translation and guide the synthesis of proteins (21,22). Moreover, circRNAs bind with specific proteins to inhibit or regulate protein activity (23,24). Furthermore, certain circRNAs may participate in development of disease, particularly in cancer. circRNAs exhibit diverse functions and may serve as diagnostic or predictive biomarkers of disease (25,26) and novel therapeutic targets. Sun et al (27) revealed that lsa_circ_0000520 may be involved in the development of gastric cancer and may therefore serve as a biomarker of the disease. Yang et al (28) demonstrated that differentially expressed circ-F-box, WD repeat domain containing 7 (FBXW7) and FBXW7-185aa have potential prognostic significance in brain cancer. However, to the best of our knowledge, the association between circRNAs and DS has not been previously reported. Therefore, it is of significance to carry out an in-depth and systematic research on circRNA of DS.

Materials and methods

Samples. Umbilical cord blood samples were obtained from 12 pregnant women, six (age range, 35-43 years; mean age, 39.7 years) carrying fetuses with DS (two male and four female) and six (27-36 years, 31.3 years of mean age) carrying fetuses without DS (two male and four female) at a gestational age of 18-22 weeks. The participants were recruited at Shenzhen People's Hospital (Shenzhen, China) between January 2013 and December 2014. Diagnosis of fetal DS was performed by chromosomal examination. In addition, peripheral blood samples were obtained from 12 children, six with DS and six without DS (two males and four females; age range, 5-12 years, mean age, 8 years) at Guilin No. 924 Hospital (Guilin, China) between January 2015 and December 2016. The present study was approved by the Ethics Committees of Shenzhen People's Hospital (Shenzhen, China) and Guilin No. 924 Hospital (Guilin, China). Written informed consent was obtained from all pregnant women and the parents/guardians of the children.

Sample processing. Ultrasound-guided umbilical cord blood extraction was performed and a total of 3 ml extracted blood was placed in EDTA-containing anticoagulant tubes. Peripheral blood (2 ml) of 12 children was extracted with a needle and placed in EDTA-containing anticoagulant tubes. According to the single nuclear cell extraction protocol, 1 ml umbilical cord blood mononuclear cells (PBMCs) was extracted using lymphocyte separation solution (MD Pacific Biotechnology Co., Ltd.), mixed with 1 ml TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), placed in cryopreservation tubes and stored at -80˚C until further use.

**Extraction of total RNA.** The frozen PBMCs were thawed at room temperature and total RNA was extracted using TRIzol® reagent according to the manufacturer's instructions. Total RNA was subsequently treated with DNase I to remove genomic DNA contamination. The purity and concentration of the RNA were determined using a spectrophotometer (NanoDrop ND-1000; Thermo Fisher Scientific, Inc.). RNA integrity was assessed using standard denaturing agarose gel electrophoresis (1%).

**circRNA labelling and array hybridization.** Total RNA from each sample was amplified and transcribed into fluorescent cRNA utilizing random primers according to the Arraystar Super RNA Labeling protocol (Arraystar, Inc.). The labelled cRNAs were hybridized onto Arraystar Human circRNA arrays (cat. no. 6X7K; Arraystar, Inc.) and incubated for 17 h at 65˚C in an Agilent hybridization oven (Agilent Technologies, Inc.). After washing, slides were scanned with the Axon GenePix 4000B Scanner (Molecular Devices, LLC).

**mRNA labelling and array hybridization.** In the present study, sample labelling and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technologies, Inc.). Briefly, total RNA from each sample was linearly amplified and labelled with Cy3-UTP (Enzo Life Sciences, Inc.). The labelled cRNAs were purified using an RNeasy Mini kit (Qiagen, Inc.). The concentration and specific activity of the labelled cRNAs (pmol Cy3/µg cRNA) were measured using a spectrophotometer. A total of 1 µg of each labelled cRNA was fragmented by the addition of 11 µl 10X blocking agent (LMAI Bio) and 2.2 µl 25X fragmentation buffer (Agilent Technologies, Inc.), then heated at 60˚C for 30 min. Subsequently, 55 µl 2X GeX Hybridization Buffer HI-RPM (Agilent Technologies, Inc.) were added to dilute the labelled cRNA and 100 µl hybridization solution (Agilent Technologies, Inc.) were dispensed into the gasket slide and assembled on the gene expression microarray slide. The slides were incubated for 17 h at 65˚C in the aforementioned Agilent hybridization oven. The hybridized arrays were washed, fixed and scanned using the Agilent DNA Microarray Scanner (cat. no. G2505C; Agilent Technologies, Inc.).

**Analysis and functional analysis of differentially expressed genes.** The differentially expressed genes (FC ≥ 2.0 or ≤ -2.0) were selected using Agilent GeneSpring GX software (version 12.1; Agilent Technologies, Inc.). Then, hierarchical clustering was performed using scripts prepared by Aksomics.
In pregnant woman carrying fetuses with and without Down’s syndrome. A total of 735 differentially expressed circRNAs were detected between the two groups, of which 414 were upregulated and 321 were downregulated (Table SI). The circRNA expression profile in the two groups is presented in Fig. 1A.

A scatter-plot was used to visualize the variation (or reproducibility) of circRNA expression between two groups of samples. The values of the x- and y-axes in the scatter-plot were the normalized signal values of the samples (log2 scaled) or the averaged normalized signal values of groups of samples (log2 scaled). The green lines represented FCs. The circRNAs above the top green line and below the bottom green line indicated a ±2.0-FC in circRNA expression between the two groups.

**Differential expression analysis of mRNA in umbilical cord blood samples.** mRNAs with a FC≥2.0 or ≤‑2.0 were selected as the differentially expressed ones. In the umbilical cord blood samples obtained from pregnant woman carrying fetuses with and without DS, 6,619 differentially expressed genes were detected, of which 3,411 and 3,208 genes were upregulated and downregulated, respectively (Table SII). The mRNA expression profile of the two groups is shown in Fig. 1B.

**RT-qPCR to validate circRNA expression.** A total of six differentially expressed circRNAs in the microarray experiments were randomly selected and the relative expression was calculated using the 2^ΔΔCq method (29). The circRNAs included three upregulated circRNAs (hsa_circRNA_103135, hsa_circRNA_103127 and hsa_circRNA_103112) and three downregulated circRNAs (hsa_circRNA_103137, hsa_circRNA_104907 and hsa_circRNA_101116). The results were validated using peripheral blood samples obtained from children with and without DS (Table I).

As seen in Table I, there were no significant differences in the expression levels of hsa_circRNA_103135, hsa_circRNA_103137 and hsa_circRNA_101116 (P>0.05), but there were extremely significant differences in the expression levels of hsa_circRNA_103127, hsa_circRNA_103112 and hsa_circRNA_104907 (P<0.01) between six children with DS and six children without DS.
Table II. Verification of differentially expressed genes in peripheral blood samples obtained from children with and without Down’s syndrome.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Fold-change</th>
<th>$2^{-\Delta\Delta Cq}$ value</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dual specificity tyrosine phosphorylation regulated kinase 1A</td>
<td>2.64</td>
<td>1.35</td>
<td>0.190</td>
</tr>
<tr>
<td>Ubiquitin specific peptidase 25</td>
<td>2.04</td>
<td>0.84</td>
<td>0.009</td>
</tr>
<tr>
<td>Spermatid perinuclear RNA binding protein</td>
<td>-4.51</td>
<td>1.35</td>
<td>0.150</td>
</tr>
</tbody>
</table>

Table III. Primers used for PCR.

<table>
<thead>
<tr>
<th>Primer sequence (5’→3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene</td>
</tr>
<tr>
<td>β-actin (Human)</td>
</tr>
<tr>
<td>hsa_circRNA_103135</td>
</tr>
<tr>
<td>hsa_circRNA_103127</td>
</tr>
<tr>
<td>hsa_circRNA_103112</td>
</tr>
<tr>
<td>hsa_circRNA_103137</td>
</tr>
<tr>
<td>hsa_circRNA_104907</td>
</tr>
<tr>
<td>hsa_circRNA_101116</td>
</tr>
<tr>
<td>USP25</td>
</tr>
<tr>
<td>DYRK1A</td>
</tr>
<tr>
<td>STRBP</td>
</tr>
</tbody>
</table>

circRNA, circular RNA; USP25, ubiquitin specific peptidase 25; DYRK1A, dual specificity tyrosine phosphorylation regulated kinase 1A; STRBP, spermatid perinuclear RNA binding protein.

Figure 1. Scatter plots of differentially expressed circRNA and mRNA. (A) Scatter plot of differentially expressed circRNA of women carrying fetuses with DS and women carrying fetuses without DS. (B) Scatter plot of differentially expressed mRNA of women carrying fetuses with DS and women carrying fetuses without DS. The higher the index signal value of the X and Y axes detected in the scatter plot, the darker the color. Absolute value of FC between the two samples was >2.0 for data above the top green line and below the bottom green.

tyrosine phosphorylation regulated kinase 1A (DYRK1A), ubiquitin specific peptidase 25 (USP25) and spermatid perinuclear RNA binding protein (STRBP), corresponding to three circRNAs (hsa_circRNA_103127, hsa_circRNA_103112...
and hsa_circRNA_104907) were validated in peripheral blood samples obtained from children with and without DS. The results are shown in Table II.

As seen in Table II, there was no significant difference in the expression levels of DYRK1A and STRBP (P>0.05), but there was extremely significant difference in the expression level of USP25 (P<0.01) between six children with DS and six children without DS.

**GO analysis of the differentially expressed genes.**

GO analysis of the differentially expressed genes revealed that 805 genes were associated with the biological process domain, of which 315 were upregulated (Fig. 2A) and 490 were down-regulated (Fig. 2B). The five most enriched biological process terms were ‘cellular processes’, ‘primary metabolic processes’, ‘cellular metabolic processes’, ‘biological regulation’ and ‘nitrogen compound metabolic processes’. A total of 189 genes were associated with the molecular function domain, of which 66 were upregulated (Fig. 3A) and 123 genes were downregulated (Fig. 3B). The five most enriched cell composition terms were ‘intracellular’, ‘intracellular part’, ‘organelle’, ‘intracellular organelle’ and ‘membrane-bound organelle’. A total of 155 genes were associated with the cellular component domain, of which 77 were upregulated (Fig. 4A) and 78 were down-regulated (Fig. 4B). The five most enriched molecular function terms were ‘binding’, ‘protein binding’, ‘RNA binding’, ‘ligase activity’ and ‘catalytic activity’.

**Pathway analysis of the differentially expressed genes.**

Pathway analysis of the differentially expressed genes allows the identification of genes related to specific cell pathways. Pathway analysis revealed that the differentially expressed genes were significantly enriched in 73 pathways (Fig. 5A and B). The upregulated genes were involved in 23 pathways and the downregulated genes were involved in 50 pathways. Differentially expressed genes were mainly involved in ‘adhesive spots’, ‘ECM-receptor interactions’, ‘gap junctions’, ‘protein digestion and absorption’, ‘vitamin digestion and absorption’ and ‘TNF signalling pathway’. Additional pathways included ‘primary immunodeficiency’, ‘systemic lupus erythematosus’, ‘rheumatoid arthritis’, ‘type I diabetes
SUI et al.: DIFFERENTIAL EXPRESSION PROFILE OF circRNA FOR DOWN’S SYNDROME

Interaction between differential expression of circRNAs and miRNAs. Endogenous circRNAs function as miRNA sponges, which means that the circRNAs bind miRNAs and repress their function (13,18,25).

A total of 3,263 MREs of differentially expressed circRNAs were described bioinformatically using the Arraystar miRNA target prediction software. Analysis of the MRE sequence showed several binding sites between hsa_circRNA_103112 and various miRNAs. There were five binding sites between hsa_circRNA_103112 and hsa-miR-20b-3p, hsa-miR-93-3p, hsa-miR-370-3p, hsa-miR-520d-3p or hsa-miR-651-3p. The sequence of hsa_circRNA_103112 was complementary to: i) The miR-20b-3p seed region at the 5’ end at position 61-66 with 7mer-m8 binding; ii) the miR-93-3p seed region at the 5’ end of the nucleotide at position 142-147 with 7mer-m8 binding; iii) the miR-370-3p seed region at the 5’ end at position 143-148 with 8mer binding; iv) the miR-520d-3p seed region at the 5’ end at position 172-177 with 7mer-m8 binding; and v) the miR-651-3p seed region at the 5’end at position 112-117 with 8mer binding. This indicated that hsa_circRNA_103112 could function as a sponge for miR-20b-3p, miR-93-3p, miR-370-3p, miR-520d-3p and miR-651-3p (Fig. 6).

The MRE sequence and the target miRNA seed type (7mer-m8, 8mer) and 3’pairing sequence (nucleotides 13-16) are presented in Fig. 6. The precise base positions are shown in the alignments in the upper left and right corners. The seed type 7mer-m8 shows an exact match to positions 2-8 of the target miRNA (the seed + position 8), and 8mer shows an exact match to positions 2-8 of the target miRNA (the seed + position 8). Adenosine/uracil (A/U) content 30 nt upstream and downstream of the seed sequence is shown in the column Local AU. Black bars represent guanine/cytosine and low accessibility whereas red bars represent A/U and high accessibility of the seed. The height of the bars shows the extent of the accessibility. The position column presents the most likely relative MRE position on the linear presentation of the circRNA.

Interaction between differentially expressed circRNAs and mRNAs. circRNAs use their MRE to bind to miRNAs and consequently repress their function. Therefore, miRNAs can...
identify the mRNA of a particular coding sequence by base complementary pairing, affecting the translation process and thus playing a role in regulating gene expression (32). The present study investigated the expression profiles of differentially expressed circRNA and mRNA and conducted an association analysis between circRNAs and mRNAs. A total of 254 circRNA transcripts were found in the corresponding differential mRNA expression profile information. Among the 254 circRNA associated with mRNA, there were 153 upregulated circRNAs and 101 downregulated circRNAs, indicating that these identical genes may regulate the occurrence and development of Down's syndrome through circRNA/miRNA/mRNA interactions. The results are presented in Fig. 7.

**Discussion**

At present, prenatal screening mainly in the early pregnancy and in the second trimester, ultrasound screening, maternal serum screening, and joint screening programs are used to assess the risk of fetal DS (33,34). However, the false negative and false positive rates of traditional prenatal screening are relatively high (35), and invasive prenatal diagnosis methods such as amniocentesis, chorionic sampling and umbilical cord blood collection can easily lead to bleeding, infection, miscarriage and other complications (36). Therefore, it is necessary to identify novel biological markers in maternal blood to further improve the prenatal screening for DS during pregnancy.

Wu et al (37) reported that circRNAs may be used as biomarkers for the diagnosis of disease and evaluation of therapeutic efficacy. In addition, due to their high stability, circRNAs are easily obtained from body fluids (10,18). Therefore, there has been increased interest in the in-depth and systematic research on circRNA. In view of the aforementioned study, under physiological conditions, the expression of circRNA in serum and plasma is relatively stable, while under pathological conditions; specific circRNA expression is likely to be abnormal.

The present study screened for differentially expressed circRNAs in umbilical cord blood obtained from pregnant women carrying fetuses with and without DS using circular gene chip technology. As a result, 735 differentially expressed circRNAs were detected, of which 414 were upregulated and 321 were downregulated. RT-qPCR was subsequently
used to validate the differential expression of circRNA in peripheral blood samples obtained from children with and without DS. A total of six differentially expressed circRNAs, including three upregulated circRNAs (hsa_circRNA_103135, hsa_circRNA_103127 and hsa_circRNA_103112) and three downregulated circRNAs (hsa_circRNA_103137, hsa_circRNA_104907 and hsa_circRNA_101116) were selected for further analysis. Quantification using the 2^ΔΔCq method (29) revealed that the six circRNAs were differentially expressed between children with and without DS. There were extremely significant differences in hsa_circRNA_103127, hsa_circRNA_103112 and hsa_circRNA_104907 expression, but no significant differences in the expression of hsa_circRNA_103135, hsa_circRNA_103137 and hsa_circRNA_101116. These differences may be related to the temporal and tissue specificity of circRNA expression. Furthermore, analysis using Arraystar's miRNA target prediction software revealed that hsa_circRNA_103112 was associated with hsa-miR-20b-3p, hsa-miR-93-3p, hsa-miR-370-3p, hsa-miR-520d-3p and hsa-miR-651-3p.

Stamova et al (38) revealed that decreased miR-93-3p expression in the superior temporal sulcus (a region relevant to social interaction) and primary auditory cortex, and may have a potential impact on autism spectrum disorder (ASD). ASD is a neurodevelopmental disorder disease, the core symptoms of which include deficits in social communication and language, as well as ritual stereotyped behaviour, learning disability, immune system disturbances and sensory system alterations (39). Furthermore, Yanni et al (40) revealed that increased expression of endogenous miR-370-3p contributes to bradycardia associated with heart failure, suggesting that miR-370-3p may serve as a therapeutic target. The aforementioned phenotypic traits are often associated with DS (41,42).

An Agilent expression profile chip was used to obtain the differentially expressed genes between pregnant women carrying fetuses with or without DS in the present study. A total of 6,619 differentially expressed genes were identified, of which 3,411 were upregulated and 3,208 were downregulated. Moreover, three genes (DYRK1A, USP25 and STRBP) corresponding to three significantly differentially expressed circRNAs (hsa_circRNA_103127, hsa_circRNA_103112 and hsa_circRNA_104907) were verified in peripheral blood samples obtained from children with and without DS. There was no significant difference in the expression level of DYRK1A and STRBP (P>0.05). However, an extremely significant difference in USP25 expression was observed (P<0.01).

Valero et al (43) revealed that USP25 is a specific ubiquitin protease gene located in the 21q11.2 region, and that an increase in USP25 gene dosage in patients with DS
disturbed the balance between ubiquitinated and deubiquitinated substrates. USP25 is a newly described member of the ubiquitin-specific processing proteases (UBPs) that encode the ubiquitin C-terminal hydrolases. Ubiquitin is a highly conserved eukaryotic protein (76 aa) and plays an important role in intracellular protein degradation. USP25 is associated with testis development and could be involved in the defective spermiogenesis found in males with DS (43). Increasing

Figure 6. Results of target prediction and sequence analysis of miRNA response elements. miR/miRNA, microRNA; circRNA, circular RNA.

Figure 7. Common genes of related circRNA-mRNA. Transcripts of 254 differentially expressed circRNAs were also found to be differentially expressed in 6,619 mRNAs. A total of 254 of the 6,619 differentially expressed mRNAs corresponded to transcripts of differentially expressed circRNA. circRNA, circular RNA; DS, Down's syndrome.
numbers of studies have found that disruption of ubiquitin systems can lead to a number of human diseases, including neurodegenerative disorders and several carcinomas (44-46). Valero et al (44) evaluated the expression level of USP25 in human fetal brains of DS and control disomic samples by RT-qPCR analysis and found an average 1.7-fold increase in USP25 expression in DS samples. Uregulation of USP25 in DS fetal brain indicates that it participates in the pathogenesis of DS and has the same gene dose effect as other UBP members associated with aneuploidy syndromes, such as ubiquitin specific peptidase 9 X-linked in Turner syndrome (47) and USP18 in DiGeorge syndrome (48).

The present study revealed that circRNA had an adsorption effect on miRNA, and the transcripts of differentially expressed circRNA were found in the corresponding differentially expressed gene expression profiles. A previous study demonstrated that miRNAs identify the mRNA of a particular coding sequence by complementary base pairing, affecting the translation process (49). Therefore, there is an interaction between circRNA/miRNA/mRNA, which may impact the occurrence and development of DS.

The present study, to best of our knowledge, was the first to reveal that circRNAs are differentially expressed between DS and control samples. The identified differentially expressed genes are mainly involved in cell division and development process and are also involved in primary immunodeficiency, rheumatoid arthritis and type I diabetes mellitus, as well as homologous recombination processes, and may result in abnormal copies of chromosome 21. This may disrupt normal development, causing patients with DS to experience developmental defects of the immune system and the emergence of various clinical symptoms (5). Most importantly, hsa_circRNA_103112 not only showed significant expression differences in cord blood, but also showed significant differences in the peripheral blood. Therefore, upregulation of hsa_circRNA_103112 and its corresponding gene, USP25, in patients with DS may result in an expression imbalance of diploid genes through circRNA-miRNA-mRNA interactions and participates in the pathogenesis of DS. In addition, the present study revealed that the differential expression of hsa_circRNA_103112 in peripheral blood may serve as a novel diagnostic marker for the non-invasive prenatal screening for DS.

The present study had a number of limitations. Firstly, the study was limited by the small number of samples, which was not large enough to establish definitive conclusions. Furthermore, the samples were collected from Shenzhen People’s Hospital and Guilin No. 924 Hospital, which may result in regional differences. Secondly, the results may not be applicable to the general population. Thirdly, the study of circRNAs in DS is still in its initial stages, and the functional analysis requires further confirmation. Therefore, further circRNA expression studies with larger sample sizes, miRNA microarray analysis, RT-qPCR validation and circRNA knock-out or overexpression studies are required to further evaluate the potential of circRNAs in DS.

Acknowledgements

Not applicable.

Funding

The present study was supported by grants from the Guangxi Science and Technology Program (grant no. 1598012-25), Science and Technology Planning Project of Guangdong Province (grant no. 2017B020209001), Natural Science Foundation of Guangdong Province (grant no. 2017A030310629), Science and Technology Plan of Shenzhen (grant no. JCYJ20170307095606266) and Natural Science Foundation of Guangdong Province (grant no. 2016A020215027).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

WS, DT and YD designed the study, analyzed the data and drafted the manuscript. YC, MO, JC, HL, WX, YW and HH acquired patient data and performed laboratory experiments. QG contributed to the study design and writing of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of Shenzhen People’s Hospital (reference number, LL-KT-201801184) and the Ethics Committee of Guilin No. 924 Hospital. Written informed consent was obtained from all pregnant women and parents/guardians of the children.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


